Silo Pharma Inc. (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems with a wholly owned managed AI agent platform, has announced its participation in the IPAC-RS 2026 Nasal Innovation Forum. The event, scheduled for September 16-17, 2026, in Jersey City, New Jersey, will bring together experts in nasal drug development, providing a platform for Silo to discuss its advancements in this specialized field.
CEO Eric Weisblum emphasized the importance of the forum, stating that it offers an opportunity to engage with key opinion leaders as the company continues to advance SPC-15, its novel nose-to-brain approach for targeted drug delivery in the treatment of post-traumatic stress disorder (PTSD). The company's focus on this delivery method could represent a significant shift in how psychiatric conditions are treated, potentially offering faster onset and improved bioavailability compared to traditional oral or injectable routes.
Supporting this potential, Silo reported preclinical data demonstrating that the SPC-15 formulation and device met predefined specifications for assay, impurities, pH, and microbiological quality over a nine-month period. Additionally, six-month accelerated stability data were consistent with long-term data, indicating the product's robustness. These results are crucial for regulatory submissions and eventual commercialization, as they provide evidence of the product's reliability and shelf-life.
The nasal innovation forum is organized by IPAC-RS, an international association focused on inhalation and nasal drug products. Silo's participation underscores its commitment to staying at the forefront of drug delivery technologies. The company's pipeline includes SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, as well as preclinical assets targeting Alzheimer's disease and multiple sclerosis, all of which could benefit from advanced delivery systems.
This announcement comes at a time when the psychiatric drug market is evolving, with a growing emphasis on rapid-acting treatments and patient-friendly administration methods. If SPC-15 successfully navigates clinical trials, it could address a significant unmet need for PTSD patients who often face challenges with adherence to daily oral medications. The nose-to-brain route may also allow for lower doses, potentially reducing systemic side effects.
Investors and industry watchers will likely view this development as a positive signal for Silo's technical capabilities and strategic direction. The company's collaboration with leading universities and laboratories, as mentioned in the press release, adds credibility to its research efforts. As the forum approaches, more details about SPC-15's clinical progress may emerge, offering further insights into its potential impact on the CNS therapeutic landscape.
For more information about Silo Pharma, visit the company's newsroom at https://ibn.fm/SILO. To view the full press release, visit https://ibn.fm/Dy4qf.
